<DOC>
	<DOCNO>NCT02599480</DOCNO>
	<brief_summary>This study ass efficacy mirabegron , new beta3-adrenergic receptor prevention heart failure . This two arm , prospective , randomize , placebo-controlled , multi-centric european phase IIb trial placebo mirabegron distribute 1:1 fashion . The patient enrol cardiac structural remodel without symptom heart failure ( maximum NYHA II ) . Patients monitor change leave ventricular mass ( assessed cardiac MRI ) and/or change diastolic function ( assessed echocardiography ) 12 month treatment .</brief_summary>
	<brief_title>Assessment Efficacy Mirabegron , New beta3-adrenergic Receptor Prevention Heart Failure</brief_title>
	<detailed_description>Background Heart failure ( HF ) represent major grow public health burden . Patients HF classically divide two group : HF preserve ejection fraction ( HFpEF ) , HF reduce ejection fraction ( HFrEF ) . As HF progressive disorder increase age , proportion patient rise due age population . Beside cost , HFpEF also put heavy burden quality life ( mostly elderly ) patient , loss autonomy dyscomfort repeat hospitalisation . Therefore , HFpEF chronic , costly , debilitating disease . A major contributor HFpEF myocardial remodelling , e.g . hypertrophy fibrosis , well cellular functional/structural modification lead alteration contractile property ventricular distensibility . Unfortunately , currently evidence-based treatment strategy . Study claim The propose clinical trial provide proof concept human clinical efficacy novel therapeutic concept : β3AR activation attenuate/prevent cardiac remodeling . Recently , new , specific agonist human β3-AR ( mirabegron ) high benefit/risk balance develop marketed clinical use non-cardiovascular disease ( overactive bladder disease ) . The trial test drug repurposing mirabegron prevention cardiac remodel lead HFpEF . Using pre-clinical model , investigator demonstrate activation β3AR attenuate myocardial hypertrophy fibrosis response neurohormonal hemodynamic stress , without compromise LV function . Therefore , recent availability new drug offer possibility test potential benefit mirabegron ( vs placebo ) add-on therapy ( top standard care ) prevent/delay myocardial remodelling patient high risk develop HFpEF . Who participate ? Patients structural cardiac disease without HF symptom ( max . NYHA 2 ) . What study involve ? Patients request go 5 time hospital perform cardiac MRI ( 3X ) , echocardiography ( 3X ) , exercise tolerance test ( 2X ) , Pet scan ( 2X ) blood sampling ( 4X ) . Who sponsor ? The Université catholique de Louvain ( UCL ) academic sponsor Prof. Jean-Luc Balligand principal coordinator study . Who fund study ? Beta3_LVH investigator-initiated project fund Horizon 2020 grant European Commission .</detailed_description>
	<mesh_term>Hypertrophy</mesh_term>
	<mesh_term>Hypertrophy , Left Ventricular</mesh_term>
	<mesh_term>Adrenergic Agents</mesh_term>
	<mesh_term>Mirabegron</mesh_term>
	<criteria>Age 18 90 year Arterial hypertension stable therapy accord current guideline algorithm ( include stable medication least four week inclusion ) , Morphological sign structural cardiac remodelling echocardiography , i.e . increase LV mass index ( 110 g/m2 high female ; 134 g/m2 high male subject ( Devereux , Reichek 1977 ) ) enddiastolic wall thickness &gt; 13 mm least one wall segment Patients may atrial fibrillation ( AF ) , wellregulated ventricular response , i.e . heart rate &lt; 100/min ( RACE II ( Groenveld et al . 2013 , 2013 ) ) , Written inform consent For subject unable read and/or write , oral inform consent observe independent witness acceptable subject fully understood oral information give Investigator . The witness sign consent form behalf subject . Unstable hypertension systolic BP≥160 mm Hg and/or diastolic BP≥100 mm Hg ( base office measurement , ambulatory measurement ) Documented ischemic cardiac disease History hospitalization overt heart failure within last 12 month Patients heart transplantation Genetic hypertrophic dilate cardiomyopathy Dysthyroidism . Severe valvulopathy NYHAclass &gt; II BMI &gt; 40 kg/m2 EF &lt; 50 % , regardless symptom Known cause ( i.e . COPD ) respiratory dysfunction ; patient positive pressure ( CPAP ) treatment sleep apnea syndrome may include , provide regular treatment least one year inclusion study eGFR &lt; 30 ml/min ( MDRD formula ) Abnormal liver function test Type I diabetes , complicate type II diabetes Patients anemia Patients bladder outlet obstruction Patients use antimuscarinic cholinergic drug treatment OAB Current use digitalis , bupranolol , propranolol , nebivolol Patients continuously treat Sildenafil PDE5 inhibitor . Current use antifungal azole derivative ( fluconazole , itraconazole , miconazole , posaconazole , voriconazole ) Current treatment mirabegron indication future treatment mirabegron due indication Contraindication MRI Pregnant nursing woman Participation interventional trial Fertile woman ( within two year last menstruation ) without appropriate contraceptive measure ( hormonal implant , injection , oral contraceptive , intrauterine device , partner vasectomy ) participate trial ( participant use hormonebased method inform possible effect trial medication contraception ) Contraindication mirabegron ( e.g . hypersensitivity ) components trial medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>HFpEF</keyword>
	<keyword>leave ventricular hypertrophy</keyword>
	<keyword>cardiac remodeling ,</keyword>
</DOC>